<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041015</url>
  </required_header>
  <id_info>
    <org_study_id>SKF1501</org_study_id>
    <secondary_id>CWRU-070144</secondary_id>
    <secondary_id>SB-389</secondary_id>
    <secondary_id>SB-SKF-104864A</secondary_id>
    <secondary_id>SB-SKF-1501</secondary_id>
    <secondary_id>NCI-G02-2092</secondary_id>
    <nct_id>NCT00041015</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment For Chemotherapy-Naive Patients With Extensive Disease - Small Cell Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which combination chemotherapy regimen is more effective in treating&#xD;
      extensive-stage small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare different chemotherapy regimens in treating&#xD;
      patients who have extensive-stage small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall survival of patients with chemotherapy-naive extensive stage small&#xD;
           cell lung cancer treated with cisplatin and oral topotecan vs cisplatin and etoposide.&#xD;
&#xD;
        -  Compare the response rates, response duration, and time to progression in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Compare the tolerability of these regimens in these patients.&#xD;
&#xD;
        -  Compare the patient-perceived disease status and well being in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to gender, ECOG performance status (0 vs 1 vs 2), lactate dehydrogenase (less than&#xD;
      1.5 times upper limit of normal (ULN) vs 1.5 times ULN or greater), and country. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral topotecan once daily on days 1-5 and cisplatin IV on day 5.&#xD;
&#xD;
        -  Arm II: Patients receive cisplatin IV on day 1 and etoposide IV over at least 30 minutes&#xD;
           on days 1-3.&#xD;
&#xD;
      Treatment in both arms repeats every 21 days for at least 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, prior to each course, at 4 weeks after study, and&#xD;
      then every 4 weeks for 16 weeks.&#xD;
&#xD;
      Patients are followed at 4 weeks, every 4 weeks for 16 weeks, and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 760 patients (380 per treatment arm) will be accrued for&#xD;
      this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>oral topotecan plus cisplatin IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral topotecan once daily on days 1-5 and cisplatin IV on day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin IV plus etoposide IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin IV on day 1 and etoposide IV over at least 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Cisplatin IV plus etoposide IV</arm_group_label>
    <arm_group_label>oral topotecan plus cisplatin IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Cisplatin IV plus etoposide IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <arm_group_label>oral topotecan plus cisplatin IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed extensive stage small cell lung carcinoma&#xD;
             (SCLC)&#xD;
&#xD;
          -  No prior chemotherapy for SCLC OR&#xD;
&#xD;
          -  No chemotherapy within 5 years of diagnosis of SCLC&#xD;
&#xD;
          -  Prior radiotherapy to measurable or nonmeasurable disease field allowed provided&#xD;
             radiotherapy was completed at least 6 weeks ago and the disease is demonstrated to be&#xD;
             progressing&#xD;
&#xD;
          -  No clinical signs or symptoms of brain and/or leptomeningeal metastases by CT scan or&#xD;
             MRI&#xD;
&#xD;
               -  Brain and/or leptomeningeal metastases that are asymptomatic on neurologic exam&#xD;
                  are allowed provided metastases do not require corticosteroid therapy to control&#xD;
                  symptoms&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2 times the upper limit of normal (ULN) (5 times ULN if&#xD;
             liver metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases&#xD;
             present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No pre-existing renal impairment that would preclude cisplatin use&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No clinical evidence of any gastrointestinal (GI) conditions including:&#xD;
&#xD;
               -  Removal of a portion of the stomach&#xD;
&#xD;
               -  History of recent obstruction of the GI tract&#xD;
&#xD;
               -  GI autonomic neuropathy&#xD;
&#xD;
               -  Ulcerative colitis&#xD;
&#xD;
               -  Crohn's disease&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Treatment with cyclosporine that would alter absorption or GI motility&#xD;
&#xD;
          -  No other conditions that would preclude absorption of oral topotecan&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 3 months prior to study, during,&#xD;
             and for at least 1 month after study&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other prior or concurrent malignancy within the past 5 years except adequately&#xD;
             treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or&#xD;
             localized low-grade prostate cancer&#xD;
&#xD;
          -  No other concurrent severe medical problems that would expose the patient to extreme&#xD;
             risk or preclude study compliance&#xD;
&#xD;
          -  No prior allergic reactions to compounds chemically related to study drugs&#xD;
&#xD;
          -  No pre-existing hearing impairment that would preclude cisplatin use&#xD;
&#xD;
          -  No overall medical condition for which study drugs would be inappropriate&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy for SCLC&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent chemotherapy for SCLC&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy for SCLC&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 24 hours since prior radiotherapy with no expected bone marrow suppression&#xD;
&#xD;
          -  Recovered from prior palliative radiotherapy (e.g, nausea and vomiting from radiation&#xD;
             of the epigastrium)&#xD;
&#xD;
          -  No concurrent radiotherapy for SCLC&#xD;
&#xD;
          -  No concurrent radiotherapy for palliation of bone metastases or CNS lesions unless&#xD;
             approved by the investigator&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery (a shorter period is allowed if deemed in&#xD;
             the best interest of the patient)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  More than 30 days or 5 half-lives (whichever is longer) since prior investigational&#xD;
             drugs&#xD;
&#xD;
          -  No other concurrent investigational therapy for SCLC&#xD;
&#xD;
          -  No concurrent cyclosporine&#xD;
&#xD;
          -  No concurrent drugs that would preclude absorption of oral topotecan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Levitan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

